恩必普注射液联合敏使朗治疗老年急性后循环缺血的疗效及成本效益分析

发布时间：2018-07-27 17:50

【摘要】：目的观察恩必普注射液联合敏使朗治疗老年急性后循环缺血(APCI)的疗效,及其对成本效益的影响。方法将64例APCI患者随机分为观察组和对照组各32例,均给予常规对症治疗;观察组采用恩必普注射液联合敏使朗治疗,对照组采用敏使朗治疗,疗程为2周。评价两组临床疗效,取血检测治疗前后血液流变学指标,采用超声检测双侧椎-基底动脉血流指标,计算成本效益比(C/E)。结果观察组总有效率90.6%,高于对照组的68.7%(P0.05);治疗后两组各血液流变学指标均较治疗前下降,且观察组低切血黏度、红细胞压积及血小板聚集率低于对照组(P均0.05);治疗后两组双侧椎-基底动脉血流平均流速、收缩期峰值流速均较治疗前升高,且观察组升高幅度均大于对照组(P均0.05)。观察组CE为65.52,高于对照组的56.29,但差异有没有统计学意义。结论恩必普注射液联合敏使朗可有效改善老年APCI患者的临床症状、血液流变学及椎-基底动脉血流指标,且成本效益更好。
[Abstract]:Objective to observe the efficacy of Enpip injection combined with Minzhenlong in the treatment of aged patients with acute posterior circulation ischemia (APCI) and its effect on cost effectiveness. Methods Sixty-four patients with APCI were randomly divided into observation group (n = 32) and control group (n = 32). To evaluate the clinical effect of the two groups, to measure the hemorheology before and after treatment, and to measure the blood flow of bilateral vertebrobasilar artery by ultrasound, and to calculate the cost benefit ratio (C / E). Results the total effective rate of the observation group was 90.6%, which was higher than that of the control group (68.7%) (P0.05). Hematocrit and platelet aggregation rate were lower than those of the control group (P 0.05), the mean velocity and peak systolic velocity of the bilateral vertebrobasilar artery in both groups were higher than those before treatment, and the amplitude of increase in the observation group was higher than that in the control group (P 0.05). The CE of the observation group was 65.52, which was higher than that of the control group (56.29), but the difference was statistically significant. Conclusion Enpip injection combined with Herba can effectively improve the clinical symptoms, hemorheology and vertebrobasilar artery blood flow in elderly patients with APCI, and is more cost-effective.
【作者单位】：苏州大学第一附属医院;无锡市人民医院;
【分类号】：R743.3

【相似文献】